12.01  0.01 (0.08%)		10-24 16:00
Open: 12.01 High: 12.44 Volume: 1,067		Pre. Close: 12 Low: 12.01 Market Cap: 101(M)

Short term
Mid term
Targets	6-month :	16.99	1-year :	19.4
Resists	First :	14.54	Second :	16.61
Pivot price	12.71
Supports	First :	11.21	Second :	9.32
MAs	MA(5) :	12.09	MA(20) :	13.01
	MA(100) :	11.42	MA(250) :	0
MACD	MACD :	-0.3	Signal :	0
%K %D	K(14,3) :	24.6	D(3) :	24.9
RSI	RSI(14): 41.4
52-week	High :	23.98	Low :	8.75

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ EXOZ ] has closed above bottom band by 17.6%. Bollinger Bands are 18.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	12.46 - 12.51	12.51 - 12.55
Low:	11.89 - 11.94	11.94 - 11.99
Close:	11.92 - 12.01	12.01 - 12.09

eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.

Thu, 23 Oct 2025
CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference - Lelezard

Thu, 23 Oct 2025
eXoZymes (NASDAQ: EXOZ) to present at ThinkEquity, Oct 30 at 8:00 AM in NYC - Stock Titan

Tue, 14 Oct 2025
eXoZymes Inc. Partners With B2i Digital to Spotlight the Cell-Free Next Generation of Biomanufacturing - NewMediaWire

Sat, 04 Oct 2025
eXoZymes Unveils Updated Investor Presentation - The Globe and Mail

Tue, 30 Sep 2025
Cell-Free Biomanufacturing Pioneer eXoZymes Gains Strategic Positions in Federal Innovation Institute - Stock Titan

Tue, 06 May 2025
eXoZymes Launches Spin-Out, NCTx, To Unlock A Promising Compound For Gut And Liver Health - SynBioBeta

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	8 (M)
Shares Float	6 (M)
Held by Insiders	71.7 (%)
Held by Institutions	0.8 (%)
Shares Short	15 (K)
Shares Short P.Month	16 (K)

EPS	-0.93
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.86
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-73.7 %
Return on Equity (ttm)	-310.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.94
Qtrly Earnings Growth	0 %
Operating Cash Flow	-9 (M)
Levered Free Cash Flow	-2 (M)

PE Ratio	-13.06
PEG Ratio	0
Price to Book value	13.96
Price to Sales	0
Price to Cash Flow	-11.3

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.